全文获取类型
收费全文 | 32554篇 |
免费 | 2576篇 |
国内免费 | 1254篇 |
专业分类
耳鼻咽喉 | 147篇 |
儿科学 | 325篇 |
妇产科学 | 356篇 |
基础医学 | 6366篇 |
口腔科学 | 1713篇 |
临床医学 | 2975篇 |
内科学 | 5429篇 |
皮肤病学 | 638篇 |
神经病学 | 893篇 |
特种医学 | 733篇 |
外国民族医学 | 9篇 |
外科学 | 3187篇 |
综合类 | 4543篇 |
现状与发展 | 10篇 |
预防医学 | 1622篇 |
眼科学 | 1071篇 |
药学 | 2358篇 |
5篇 | |
中国医学 | 939篇 |
肿瘤学 | 3065篇 |
出版年
2024年 | 28篇 |
2023年 | 476篇 |
2022年 | 655篇 |
2021年 | 1386篇 |
2020年 | 1062篇 |
2019年 | 994篇 |
2018年 | 1033篇 |
2017年 | 959篇 |
2016年 | 1007篇 |
2015年 | 1072篇 |
2014年 | 1693篇 |
2013年 | 1987篇 |
2012年 | 1503篇 |
2011年 | 1840篇 |
2010年 | 1453篇 |
2009年 | 1464篇 |
2008年 | 1484篇 |
2007年 | 1643篇 |
2006年 | 1471篇 |
2005年 | 1426篇 |
2004年 | 1210篇 |
2003年 | 1070篇 |
2002年 | 1059篇 |
2001年 | 948篇 |
2000年 | 805篇 |
1999年 | 697篇 |
1998年 | 617篇 |
1997年 | 583篇 |
1996年 | 477篇 |
1995年 | 419篇 |
1994年 | 477篇 |
1993年 | 420篇 |
1992年 | 344篇 |
1991年 | 294篇 |
1990年 | 330篇 |
1989年 | 223篇 |
1988年 | 222篇 |
1987年 | 185篇 |
1986年 | 178篇 |
1985年 | 265篇 |
1984年 | 201篇 |
1983年 | 140篇 |
1982年 | 159篇 |
1981年 | 109篇 |
1980年 | 90篇 |
1979年 | 65篇 |
1978年 | 50篇 |
1977年 | 47篇 |
1976年 | 31篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
31.
目的制备美洲大蠊Periplaneta americana口腔原位温敏凝胶。方法采用自由基聚合法首次以N-异丙基丙烯酰胺(NNIPAM)和甲基丙烯酸羟丙酯(HPMA)合成聚(N-异丙基丙烯酰胺-甲基丙烯酸羟丙酯)[P(NNIPAM-HPMA)]作为温敏材料;通过冷溶法制备美洲大蠊口腔原位温敏凝胶,采用Box-Behnken设计响应面法,以溶蚀时间、胶凝时间为评价指标,在固定美洲大蠊提取物用量基础上,对羟丙基甲基纤维素(HPMC)、聚乙烯吡咯烷酮(PVP K30)、P(NNIPAM-HPMA)的用量进行优选。结果通过原位聚合法合成了P(NNIPAM-HPMA)温敏材料;并用响应面法优选了可用于口腔的美洲大蠊原位温敏凝胶的处方,优选的处方为美洲大蠊提取物10%、HPMC 3.0%、PVP K30 9.5%、P(NNIPAM-HPMA) 10.0%,其溶蚀时间为2 h,胶凝时间8~9 s。结论优选得到美洲大蠊口腔原位温敏凝胶,为美洲大蠊提取物的口腔原位局部的临床应用奠定了科学依据。 相似文献
32.
目的 建立本单位应用光学表面监测系统(OSMS)门控技术在左侧乳腺癌深吸气屏气(DIBH)放疗的基本流程,比较应用OSMS与CBCT确定左侧乳腺癌DIBH放疗摆位误差的一致性。方法 20例左侧乳腺癌患者采用DIBH方法治疗,OSMS与模拟定位DIBH体表外轮廓配准,CBCT扫描与模拟定位CT配准各记录得到误差数据,数据包括左右(x)、上下(y)、前后(z)方向平移误差和旋转误差Rx、Ry、Rz。采用Pearson法分析两者相关性,Bland-Altman法检验两者一致性。结果 两种方法呈正相关,x、y、z方向平移误差以及Rx、Ry、Rz方向旋转误差的相关系数分别为0.84、0.74、0.84、0.65、0.41、0.54(P<0.01),95%CI值分别为-0.37~0.42 cm、-0.39~0.41 cm、-0.29~0.49cm和-2.9°~1.4°、-2.6°~1.4°、-2.4°~2.5°,均<5mm和3°。20例左侧乳腺癌DIBH放疗患者系统误差<0.18cm,随机误差<0.24cm。结论 左侧乳腺癌DIBH放疗中应用OSMS与CBCT两种方式确定与模拟定位状态误差具有一致性,CBCT图像引导基础上使用无辐射的OSMS验证位置信息是安全可靠的。 相似文献
33.
34.
Young Hyo Choi Min Yong Kang Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Chan Kyo Kim Byung Kwan Park Hyun Moo Lee 《Clinical genitourinary cancer》2019,17(1):e19-e25
Background
The purpose of the study was to compare cancer detection rates between 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and multiparametric magnetic resonance imaging (mpMRI)-guided target prostate biopsy (MRI-TBx) according to prostate-specific antigen (PSA) level in biopsy-naive patients.Patients and Methods
A retrospective study was conducted in 2009 biopsy-naive patients with suspected prostate cancer (PSA ≤20 ng/mL). Patients underwent TRUS-Bx (n = 1786) or MRI-guided target prostate biopsy (MRI-TBx; n = 223) from September 2013 to March 2017 and were stratified according to each of 4 PSA cutoffs. MRI-TBx was performed on lesions with Prostate Imaging Reporting and Data System (PI-RADS) scores of 3 to 5 on mpMRI. Clinically significant prostate cancer (csPCa) was defined as Gleason ≥7. Propensity score matching was performed using the prebiopsy variables, which included age, PSA, prostate volume, and PSA density.Results
Propensity score matching resulted in 222 patients in each group. There were significant differences between the TRUS-Bx and MRI-TBx groups in the overall detection rates of prostate cancer (41.4% vs. 55.4%; P = .003) and csPCa (30.1% vs. 42.8%; P = .005). However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to <4 (29.5% vs. 56.6%; P < .001). The csPCa detection rates of TRUS-Bx and MRI-TBx did not differ significantly within the PSA cutoffs. There was a significantly higher detection rate of prostate cancer and csPCa in lesions with PI-RADS scores 4 and 5 than in those with a score of 3.Conclusion
Prebiopsy mpMRI and subsequent targeted biopsy had a higher detection rate than TRUS-Bx in patients with prostate cancer and csPCa. 相似文献35.
36.
37.
38.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
39.
Matthew D. Li Katrina F. Chu Allegra DePietro Vincent Wu Eric Wehrenberg-Klee Omar Zurkiya Raymond W. Liu Suvranu Ganguli 《Journal of vascular and interventional radiology : JVIR》2019,30(3):314-319
Purpose
To evaluate the feasibility of a same-day yttrium-90 (90Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.Materials and Methods
All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC. Yttrium-90 treatment activities were calculated by body surface area method. Tumor imaging response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for liver metastases and modified RECIST for HCC. Clinical side effects and adverse events were graded per Common Terminology Criteria for Adverse Events version 4.0.Results
All planned cases were technically successful, and no cases were canceled for elevated LSF or vascular anatomic reasons. Pretreatment angiography modified the planned 90Y treatment activity in 1 case in which vascular anatomy required a lobar-dose split into 2 for segmental infusions. In 18% of cases, patients were briefly admitted after the procedure for observation or symptom management. Imaging evaluation of initial efficacy at 1 month demonstrated partial response in 25% and stable disease in 67% of patients with liver metastases and partial/complete response in 43% and stable disease in 14% of patients with HCC. Grade ≥ 3 adverse events occurred in 6% of cases, with no systemic therapy–limiting toxicities. The mean total procedure time was 4.2 hours.Conclusions
A same-day 90Y radioembolization protocol with resin microspheres is feasible in select patients, which can expedite cancer therapy. 相似文献40.
目的优化丁香苦苷聚乳酸(Syr)-羟基乙酸共聚物[poly(lactic-co-glycolic acid),PLGA]纳米粒(Syr-NPs)的处方。方法采用纳米沉淀法制备Syr-NPs,以包封率、载药量、平均粒径以及总评"归一值"为评价指标,采用星点设计-效应面法考察PLGA质量浓度(A)、丁香苦苷质量浓度(B)、水相与有机相比例(C)3因素考察对包封率、载药量、平均粒径以及总评归一值的影响,以星点设计-效应面法选取最佳处方条件进行预测分析。结果最优处方工艺为PLGA质量浓度为9.63 mg/mL,Syr质量浓度为12.88 mg/mL,有机相与水相的比例为1∶9.46,制得的Syr-NPs的包封率、载药量、平均粒径分别为(27.86±0.87)%、(7.02±0.15)%、(110.0±1.20)nm。结论该方法稳定可行,可用于优化包载Syr的PLGA纳米粒处方与制备工艺。 相似文献